Other

Shionogi Company Limited

Chugai Seiyaku Kabushiki Kaisha

Shionogi Sieyaku Kabushiki Kaisha

Kaneka Corporation

Mitsubishi Tanabe Pharma Corporation

Shionogi Seiyaku Kabushiki Kaisha

Kazuwa Nakao

Nakao, Kazuwa

Hiroo Imura

Hidetomo Kitamura

Shigetada Nakanishi

Yasushi Kondo

Fumio Osakada

Jun Yamashita

Yoshiaki Kiso

Yutaka Suzuki

Hitoshi Shirakawa

Michiteru Yoshida

Takahiro Okazaki

Akihiro Yasoda

Hiroko Uesugi

Hiroshi Itoh

Junko Sobajima

Shoichi Ozaki

Masakatsu Sone

Masao Tanaka

This invention provides a composition for increasing a body height of a patient with short stature or an individual other than patients with short stature. More specifically, the invention provides: a composition for increasing the body height of an individual comprising a guanyl cyclase B (GC-B) activator as an active ingredient, the composition being to be administered to an individual free from FGFR3 abnormality; a method for increasing the body height of an individual free from FGFR3 abnormality which comprises activating GC-B; a method for screening an agent for increasing the body height of an individual which comprises selecting an agent for increasing the body height using GC-B activity as an indication; and a method for extending a cartilage bone free from FGFR3 abnormality which comprises activating GC-B in an individual.

Method for increasing body height comprising systemic administration of CNP-53

This invention provides a new therapeutic or prophylactic agent for arthritis such as osteoarthritis. Specifically, it provides a therapeutic or prophylactic agent for arthritis such as osteoarthritis, or an agent for promoting the growth of articular chondrocyte, comprising a guanyl cyclase B (GC-B) activator as an active ingredient; or a method for inhibiting arthritis or for promoting the growth of articular chondrocyte by activating GC-B; or a method for screening an agent for promoting the growth of articular chondrocyte or an agent capable of treating arthritis using the GC-B activity as an indication.

Method of screening for an agent for treating arthritis and promoting growth of articular chondrocytes

Method of treating arthritis and promoting growth of articular chondrocytes

To provide a technique of the differentiation from a primate embryonic stem cell into a vascular cell, and techniques using the same. A method for differentiating a primate embryonic stem cell into a vascular cell, comprising differentiating a primate embryonic stem cell into a VEGFR-2-positive and undifferentiated primate embryonic stem cell marker-negative cell, and if need, further differentiating the resulting cell, a method of the differentiation into a vascular cell, and a vascular cell obtained by the method.

Method for differentiating primate embryonic stem cell into vascular cell

DNA encoding an endothelin receptor shown in SEQ ID NO: 1 or 2 in the Sequence Listing is isolated from cDNA which is prepared from poly(A)RNA derived from a human placenta. In addition, an expression vector containing the DNA and a transformant containing the expression vector are obtained. An endothelin receptor is obtained by culturing this transformant. A receptor shown in SEQ ID NO: 1 is an ET-receptor which has a high affinity for endothelins 1 and 2, especially for the endothelin 1. A receptor shown in SEQ ID NO: 2 is an ET-receptor which has an affinity for endothelins 1, 2 and 3 with no selectivity.

Human endothelin receptor

A diagnostic drug and a diagnostic kit for autoimmune diseases including at least one of a polypeptide selected from an HMG-1 family, a polypeptide selected from an HMG-2 family, a fragment thereof which is reactable with an antibody of an autoimmune disease patient, and a method for detecting an antibody of an autoimmune disease patient using the same are provided.

Diagnostic drugs for autoimmune diseases

DNA encoding an endothelin receptor shown in SEQ ID NO: 1 or 2 in the Sequence Listing is isolated from cDNA which is prepared from poly(A) RNA derived from a human placenta. In addition, an expression vector containing the DNA and a transformant containing the expression vector are obtained. An endothelin receptor is obtained by culturing this transformant. A receptor shown in SEQ ID NO: 1 is an ET -receptor which has a high affinity for endothelins 1 and 2, especially for the endothelin 1. A receptor shown in SEQ ID NO: 2 is an ET -receptor which has an affinity for endothelins 1, 2 and 3 with no selectivity.

Therapeutic agents for achondroplasia

DNA encoding an endothelin receptor shown in SEQ ID NO: 1, SEQ ID NO: 2, SEQ ID NO: 3, or SEQ ID NO: 4. In the Sequence Listing is isolated from cDNA which is prepared from poly(A),RNA derived from a human placenta. In addition, an expression vector containing the DNA and a transformant containing the expression vector are obtained. An endothelin receptor is obtained by culturing this transformant. A receptor shown in SEQ ID NO: 1 and SEQ ID NO: 2 is an ET,-receptor which has a high affinity for endothelins 1 and 2, especially for the endothelin 1. A receptor shown in SEQ ID NO: 3 and SEQ ID NO: 4 is an ET,-receptor which has an affinity for endothelins 1, 2 and 3 with no selectivity.

A monoclonal antibody which recognizes the N-terminal of .alpha.-atrial natriuretic polypeptide (.alpha.-ANP). A hybridoma producing said monoclonal antibody and a process for immunoassay of .alpha.-ANP are also provided.

Monoclonal antibody recognizing atrial natriuretic polypeptide

A monoclonal antibody which recognizes the N-terminal of gamma-atrial natriuretic polypeptide (.gamma.-ANP). A hybridoma producing said monoclonal antibody and a process for immunoassay of .gamma.-ANP are also provided.

Monoclonal antibody recognizing gamma atrial natriuretic polypeptide

The polypeptides represented by the general formula: R-Asn-Ser-Phe-Arg-Tyr-OH wherein R is H, Cys, Gly-Cys, Leu-Gly-Cys, Gly-Leu-Gly-Cys, Ser-Gly-Leu-Gly-Cys, Gln-Ser-Gly-Leu-Gly-Cys, Ala-Gln-Ser-Gly-Leu-Gly-Cys, Gly-Ala-Gln-Ser-Gly-Leu-Gly-Cys, or Ile-Gly-Ala-Gln-Leu-Gly-Cys, and the salt thereof, useful for development of reagents for clinical diagnosis of essential hypertension or in research of pathophysiology.

Growing community of inventors

Kyoto, Japan

Kazuwa Nakao